Recently, Zhejiang Chengyi Pharmaceutical Co., Ltd. announced that the company has received the "Drug Registration Certificate" for the drug Aspartate Ornithine Injection (10ml: 5g) approved and issued by the National Drug Administration. The raw material used in the preparation - Aspartate Ornithine Raw Material Drug (25kg/bag) has completed the associated evaluation with the preparation, and the current evaluation result is A, obtaining a market sales license.
Aspartate ornithine injection (10ml: 5g X 5 doses) is mainly suitable for the treatment of acute and chronic liver diseases (such as various types of hepatitis, cirrhosis, fatty liver, and post hepatitis syndrome) that cause elevated blood ammonia levels, as well as for the treatment of hepatic encephalopathy. It is particularly suitable for the treatment of early or coma conscious states in liver coma.
Experts introduce that the main reason for the effectiveness of ornithine aspartate drugs is that they produce two amino acids, including aspartic acid and ornithine. These two amino acids are involved in the synthesis of urea in the body, which can promote the excretion of toxic substances from the body and assist the liver in completing detoxification.
Zhejiang Chengyi Pharmaceutical has been researching and developing this product for over 10 years, and the company has strong technical capabilities. Obtaining the drug registration certificate this time signifies that the company has the qualification to sell the drug in the domestic market, further enriching the company's product line and helping to enhance the market competitiveness of the company's products.
Article source: Dazhong Securities News